TransCelerate BioPharma Inc. is a non-profit organization with a mission to collaborate across the global biopharmaceutical research and development community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high-quality delivery of new medicines.

TransCelerate is hosting a regular Discussion Forum for clinical technology solution providers seeking to become actively involved in further development of Digital Data Flow (DDF) solutions, including the CDISC Unified Study Definitions Model (USDM) and the Study Definitions Repository (SDR) Reference Implementation. Participation sign-up is open until June 2, 2023.

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, has joined TransCelerate BioPharma as an Associate Member.

2022's annual report details all that TransCelerate BioPharma and BioCelerate have achieved in the past year in our preclinical, clinical, and pharmacovigilance portfolio.

The TransCelerate Site Qualification and Training (SQT) Initiative has developed a Mutual Recognition (MR) Program for ICH E6 Good Clinical Practice (GCP) Training, targeted to investigator site personnel. Our GCP Mutual Recognition program was created to reduce redundant training and hours spent by investigators who need to complete the same training if they work with multiple sponsors.

TransCelerate Member Companies have translated select solutions for potential use within the broader global community. Current translations include solutions concerning Common Protocol Template, Site Qualification & Training, Quality Management Systems and Patient Experience.